Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 493
- Registration Number
- NCT00134966
- Locations
- 🇨🇦
Dr. Felix Veloso Research, Regina, Saskatchewan, Canada
🇮🇹Istituto Nazionale Neurologico "Carlo Besta", Via Celoria 11, Milano, Italy
🇮🇹Dipartimento di Scienze Neurologiche Università degli Studi di Roma "La Sapienza" Roma I, Viale dell'Università 30, Roma, Italy
Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus
- Conditions
- Coronary Heart Disease
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 100
- Registration Number
- NCT00134940
- Locations
- 🇩🇪
Novartis, Erlangen, Germany
🇦🇹Novarits, Graz, Austria
🇩🇪Novartis Investigative Site, Berlin, Germany
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
- Conditions
- Cognitive Symptoms
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00134953
A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2006-06-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00134992
- Locations
- 🇩🇪
Kopfklinik der Ruprechts-Karls- Universität, Heidelberg, Germany
Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
- Conditions
- Seasonal Allergic Conjunctivitis
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 229
- Registration Number
- NCT00133627
- Locations
- 🇨🇳
Hospital of Shanghai Medical University, Shanghai, China
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 240
- Registration Number
- NCT00132652
Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Novartis
- Registration Number
- NCT00131742
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
- Conditions
- Diabetic Retinopathy
- Interventions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 583
- Registration Number
- NCT00131144
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
- Conditions
- Diabetic Retinopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 312
- Registration Number
- NCT00130845
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Rivastigmine Capsules in Patients With Probable Vascular Dementia
- Conditions
- Vascular Dementia
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 521
- Registration Number
- NCT00130338